NEOS Neos Therapeutics Inc.

1.34
+0.04  (+3%)
Previous Close 1.3
Open 1.33
Price To Book 66.75
Market Cap 66,379,559
Shares 49,722,516
Volume 7,809
Short Ratio
Av. Daily Volume 324,836

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)

Latest News

  1. Neos Therapeutics to Present at Two Upcoming June Conferences
  2. Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
  3. Neos Therapeutics Enters Oversold Territory
  4. Edited Transcript of NEOS earnings conference call or presentation 9-May-19 12:30pm GMT
  5. Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates
  6. Neos Therapeutics: 1Q Earnings Snapshot
  7. Neos Therapeutics Reports First Quarter 2019 Financial Results
  8. Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
  9. Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  10. Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
  11. Edited Transcript of NEOS earnings conference call or presentation 14-Mar-19 12:30pm GMT
  12. Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
  13. The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
  14. Neos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
  15. Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019
  16. Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference
  17. Report: Exploring Fundamental Drivers Behind Iamgold, Malibu Boats, Renren, 58, Neos Therapeutics, and Kimball Electronics — New Horizons, Emerging Trends, and Upcoming Developments
  18. Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
  19. Teva Stock Rises on Patent Settlement With Neos Therapeutics